Straits Times Index
3,188.50 -9.58 (-0.30%) S&P 500
4,535.79 -0.40 (-0.01%) Dow
35,520.17 -89.17 (-0.25%) Nasdaq
15,175.97 +54.30 (+0.36%) BTC-USD
64,343.24 -1,621.09 (-2.46%) CMC Crypto 200
1,524.03 -10.62 (-0.69%)
SpringWorks Therapeutics, Inc. (SWTX)
| Previous close | 58.81 |
| Open | 61.88 |
| Bid | 60.21 x 1100 |
| Ask | 60.63 x 800 |
| Day's range | 58.12 - 61.88 |
| 52-week range | 51.57 - 96.48 |
| Volume | 40,250 |
| Avg. volume | 281,903 |
| Market cap | 2.941B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.87 |
| Earnings date | 10 Nov 2021 - 15 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 114.80 |
- Zacks
New Strong Sell Stocks for August 13th
LASR, TWLO, SWTX, FSLY, and UUUU have been added to the Zacks Rank #5 (Strong Sell) List on August 13, 2021
- Zacks
Precision BioSciences (DTIL) Surges 6.6%: Is This an Indication of Further Gains?
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- Business Wire
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
DURHAM, N.C. & STAMFORD, Conn., June 28, 2021--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the combination
